EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model

Iain J Abbott iD, Elke van Gorp, Hugh Cottingham, Nenad Macesic iD, Steven C Wallis iD, Jason A Roberts iD, Joseph Meletiadis iD, Anton Y Peleg iD

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkac402 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Iain J Abbott und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Urinary Tract Infections, Cystitis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Australian National Health and Medical Research Council, NHMRC, Practitioner Fellowships.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Pharmacodynamic profiling of oral ciprofloxacin dosing for urinary tract infections caused by ceftriaxone-resistant Escherichia coli isolates with ciprofloxacin MIC ≥ 0.25 mg/L.

Background

Urine-specific breakpoints for ciprofloxacin do not exist. However, high urinary concentrations may promote efficacy in isolates with low-level resistance.

Methods

Ceftriaxone-resistant E. coli urinary isolates were screened for ciprofloxacin susceptibility. Fifteen representative strains were selected and tested using a dynamic bladder infection model. Oral ciprofloxacin dosing was simulated over 3 days (250 mg daily, 500 mg daily, 250 mg 12 hourly, 500 mg 12 hourly and 750 mg 12 hourly). The model was run for 96 h. Primary endpoint was change in bacterial density at 72 h. Secondary endpoints were follow-up change in bacterial density at 96 h and area-under-bacterial-kill-curve. Bacterial response was related to exposure (AUC0–24/MIC; Cmax/MIC). PTA was determined using Monte-Carlo simulation.

Results

Ninety-three clinical isolates demonstrated a trimodal ciprofloxacin MIC distribution (modal MICs at 0.016, 0.25 and 32 mg/L). Fifteen selected clinical isolates (ciprofloxacin MIC 0.25–512 mg/L) had a broad range of quinolone-resistance genes. Following ciprofloxacin exposure, E. coli ATCC 25922 (MIC 0.008 mg/L) was killed in all dosing experiments. Six isolates (MIC ≥ 16 mg/L) regrew in all experiments. Remaining isolates (MIC 0.25–8 mg/L) regrew variably after an initial period of killing, depending on simulated ciprofloxacin dose. A >95% PTA, using AUC0–24/MIC targets, supported 250 mg 12 hourly for susceptible isolates (MIC ≤ 0.25 mg/L). For isolates with MIC ≤ 1 mg/L, 750 mg 12 hourly promoted 3 log10 kill at the end of treatment (72 h), 1 log10 kill at follow-up (96 h) and 90% maximal activity (AUBKC0–96).

Conclusions

Bladder infection modelling supports oral ciprofloxacin activity against E. coli with low-level resistance (ciprofloxacin MIC ≤ 1 mg/L) when using high dose therapy (750 mg 12 hourly).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Tract InfectionsCystitisHumansCiprofloxacinCeftriaxoneEscherichia coliUrinary BladderBacteriaMicrobial Sensitivity TestsAnti-Bacterial Agents

Substanzen

CiprofloxacinCeftriaxoneAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia.
  • University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
  • Department of Intensive Care Medicine and Pharmacy Department, Royal Brisbane and Women's Hospital, Brisbane, Australia.
  • Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, Nîmes, France.
  • Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Haidari, Athens, Greece.
  • Infection and Immunity Program, Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, VIC, Australia.

ORCID-Profile: Iain J Abbott, Nenad Macesic, Steven C Wallis, Jason A Roberts, Joseph Meletiadis, Anton Y Peleg

Förderung

  • Australian National Health and Medical Research Council
  • NHMRC
  • Practitioner Fellowships
  • Australian National Health and Medical Research Council for a Centre of Research Excellence
  • Investigator Grant

Zitieren

APA

Abbott, I. J., van Gorp, E., Cottingham, H., Macesic, N., Wallis, S. C., Roberts, J. A., Meletiadis, J., & Peleg, A. Y. (2023). Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkac402

Vancouver

Abbott IJ, van Gorp E, Cottingham H, Macesic N, Wallis SC, Roberts JA, et al. Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkac402

BibTeX
@article{Abbott2023,
  author = {Abbott, Iain J and van Gorp, Elke and Cottingham, Hugh and Macesic, Nenad and Wallis, Steven C and Roberts, Jason A and Meletiadis, Joseph and Peleg, Anton Y},
  title = {Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkac402}
}
Kostenlos starten →